{
    "clinical_study": {
        "@rank": "31775", 
        "acronym": "ADCVCTAST", 
        "arm_group": {
            "arm_group_label": "Autologous dendritic cell vaccine", 
            "arm_group_type": "Experimental", 
            "description": "Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to achieving a six-month progression free survival (PFS) of\n      patients receiving autologous dendritic cell vaccine (ADKV)  loaded with allogeneic tumor\n      lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas"
        }, 
        "brief_title": "Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma", 
        "condition": [
            "Sarcoma", 
            "Neoplasms, Connective and Soft Tissue"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Testicular Neoplasms", 
                "Neoplasms, Connective and Soft Tissue", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age of 18 or older\n\n          -  ECOG performance score 0 or 1\n\n          -  Histologically proven soft tissue sarcoma\n\n          -  Unresectable or metastatic soft tissue sarcoma\n\n          -  Ability to give written informed consent\n\n          -  Objective measured and measurable tumor lesions\n\n          -  The failure of standard therapy\n\n          -  Adequate amount of material for genetic research\n\n          -  No active or chronic infection with HIV, Hepatitis B or Hepatitis C\n\n          -  Men/Women of childbearing potential must use adequate contraception\n\n          -  Hematology, liver function and renal function lab tests within required parameters\n\n        Exclusion Criteria:\n\n          -  Untreated or uncontrolled brain metastases.\n\n          -  History of other active malignancy within last 2 years, except adequately treated\n             other soft tissue sarcoma.\n\n          -  Autoimmune disease (vitiligo is not a basis for exclusion).\n\n          -  Serious uncontrolled medical disorder or active infection that would impede\n             treatment.\n\n          -  Underlying medical or psychiatric condition that would cause administration vaccine\n\n          -  Any non-oncology vaccine therapy up to 1 month before or after any dose of vaccine\n\n          -  Concomitant therapy with IL-2, interferon, other non-study immunotherapy, or\n             cytotoxic chemotherapy; immune-suppressive agents within 30 days of registration;\n             other investigational therapies; chronic use of systemic corticosteroids (however, a\n             low stable dose steroid for mild brain edema or adrenal insufficiency is allowed;\n             topical and inhaled standard dose corticosteroids are allowed).\n\n          -  Dementia or significantly altered mental status that would prohibit understanding or\n             rendering of informed consent and compliance with protocol requirements.\n\n          -  Pregnant or breastfeeding women.\n\n          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for\n             treatment of either a psychiatric or physical (e.g. infectious) illness."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883518", 
            "org_study_id": "MC-01-2013"
        }, 
        "intervention": {
            "arm_group_label": "Autologous dendritic cell vaccine", 
            "description": "Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens", 
            "intervention_name": "Autologous dendritic cell vaccine", 
            "intervention_type": "Biological", 
            "other_name": [
                "Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens", 
                "CTA vaccine", 
                "DC vaccine", 
                "DC CTA vaccine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fibrosarcoma", 
            "Neurofibrosarcoma", 
            "Histiocytoma", 
            "Histiocytoma, Malignant Fibrous", 
            "Chondrosarcoma", 
            "Synovial Sarcoma", 
            "Leiomyosarcoma", 
            "Liposarcoma", 
            "Myosarcoma", 
            "Rhabdomyosarcoma", 
            "Sarcoma, Alveolar Soft Part", 
            "NY-ESO-1", 
            "MAGE", 
            "MAGE A3", 
            "Vaccine", 
            "Immunotherapy"
        ], 
        "lastchanged_date": "June 19, 2013", 
        "location": {
            "contact": {
                "email": "anofelesof@gmail.com", 
                "last_name": "Yury Komarov, MD", 
                "phone": "4399505", 
                "phone_ext": "+7812"
            }, 
            "facility": {
                "address": {
                    "city": "Saint-Petersburg", 
                    "country": "Russian Federation", 
                    "zip": "197758"
                }, 
                "name": "Petrov Research Institute of Oncology"
            }, 
            "investigator": {
                "last_name": "Yury Komarov, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "1", 
        "official_title": "Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma", 
        "overall_contact": {
            "email": "anofelesof@gmail.com", 
            "last_name": "Yury Komarov, MD", 
            "phone": "4399505", 
            "phone_ext": "+7812"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Russia: Ethics Committee", 
                "Russia: The Ministry of Education and Science of the Russian Federation", 
                "Russia: Ministry of Health of the Russian Federation"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Achieving a six-month time to progression (PFS) 40% of patients receiving ADKV loaded with allogeneic tumor lysate expressing PTA in patients with soft tissue sarcomas", 
            "measure": "Achieving a six-month progression free survival (PFS) of patients receiving ADKV  with soft tissue sarcomas", 
            "safety_issue": "No", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883518"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Median progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "measure": "Median overall survival", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "6 mounth"
            }, 
            {
                "description": "Grade of Allergic reaction/hypersensitivity, Autoimmune reaction, Fever, Injection site reaction by CTCAE v 4.0", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "6 mounth"
            }, 
            {
                "description": "\u0421hanging level of T lymphocytes subpopulation in peripheral blood", 
                "measure": "Assess biological response of tumors", 
                "safety_issue": "No", 
                "time_frame": "6 mounth"
            }
        ], 
        "source": "Petrov Research Institute of Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Petrov Research Institute of Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}